Tokyo, Japan, 06, 08, 2023 – Curreio, Inc. (Curreio), a Japanese company specializing in structural analysis of biomolecules using cryo-electron microscopy, and Iktos, a company specialized in Artificial Intelligence for new drug design, today announced a collaboration agreement in AI for new drug design. In this collaboration, Curreio’s state-of-the-art cryo-EM platform in combination with Iktos’ de […]

Tokyo, June 1st –Curreio Inc. (Curreio), a leading Cryo-Electron Microscopy (Cryo-EM) based Structure Based Drug Designing (SBDD) company, is pleased to announce the appointment of Dr. Akiyoshi Shimaya as its new Chief Scientific Officer (CSO). Dr. Shimaya brings a wealth of expertise and a distinguished career in drug discovery at Japanese mega pharma to further […]

Curreio Inc. raised approximately 260 million yen through a third-party allotment of new shares to funds managed by Beyond Next Ventures Inc., T&D Innovation Fund, Asahi Kasei Pharma Corporation, 3S Capital, Inc., U-Tokyo Entrepreneur Supporter’s Club Incubation Fund, IKERUNippon Capital Partners, DOJIN Capital, Ono Venture Investment, Inc., and others. This significantly contributes to strengthen our […]